蔡华

Cooley advised underwriters on IGM Biosciences’ $201.3 million initial public offering of 12,578,125 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Piper Jaffray, Stifel, Nicolaus & Company and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences’ securities now trade on the Nasdaq Global Select Market under the symbol “IGMS.” Partners Jonie Kondracki, Charlie Kim, Dave Peinsipp and Will Cai led the Cooley team.

Cooley advised underwriters on Phathom Pharmaceuticals' $209 million initial public offering of 10,997,630 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Needham & Company acted as the lead manager for the offering. Goldman Sachs & Co. LLC, Jefferies and Evercore ISI acted as joint book-running managers for the offering. Phathom Pharmaceuticals' securities now trade on the Nasdaq Global Market under the symbol “PHAT.” Charlie Kim, Sean Clayton, Jonie Kondracki and Will Cai led the Cooley team.

Cooley advised Fangdd on its $78 million initial public offering of 6,000,000 American depositary shares, each representing 25 class A ordinary shares. The underwriters have a 30-day option to purchase up to 900,000 additional shares. The transaction represents Cooley’s first completed IPO out of its newly launched Hong Kong office. Partner Will Cai led the Cooley team advising Fangdd. Founded in 2011 by former real estate agents Yi Duan and Xi Zeng, Fangdd now trades its securities on the Nasdaq Global Select Market under the symbol “DUO.”

Cooley advised EHang Holdings on its $40 million initial public offering of 3,200,000 shares of American Depository Shares. EHang Holdings, whose securities now trade on the Nasdaq Global Market under the symbol “EH,” is an autonomous aerial vehicle (“AAV”) technology platform company. Partners Will Cai, Charlie Kim, and Dave Peinsipp led the Cooley team.

Cooley advised ORIC Pharmaceuticals on its $138 million initial public offering of 8,620,000 shares of common stock, including full exercise of the underwriter's option to purchase additional shares. ORIC Pharmaceuticals, whose securities now trade on the Nasdaq Global Select Market under the symbol “ORIC”, is a developer of novel therapies intended to overcome resistance in cancer. Partners Charlie Kim, Sean Clayton, Kristin VanderPas and Will Cai led the Cooley team.